Beta Thalassemia clinical trials
22 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
- Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
- ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
- Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
- Study of the Role of Genetic Modifiers in Hemoglobinopathies
- Discarded Bone Marrow for Hematology Research
- Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
- FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
- Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
- Allo HSCT for High Risk Hemoglobinopathies
- Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy
- A Long-term Follow-up Study in Participants Who Received CTX001
- A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
- Early Check: Expanded Screening in Newborns
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Beta Thalassemia” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.